Filling the need for trusted information on health issues…

Trending on kff Enrollment Marketplaces Medicare Advantage

Tuberculosis

  • your selections
Clear Search

Filter Results

date

Tags

  • results
Global Fund Approves $2.4B For Ninth Round Grants

During its recent board meeting in Addis Ababa, Ethiopia, the Global Fund to Fight AIDS, Tuberculosis and Malaria approved $2.4 billion for the three diseases, PlusNews reports. The money is for the fund’s “ninth round of grants, bringing the total amount of approved funding since its inception in 2001 to $18.4 billion,” according to the publication.

GlobalPost Examines Investment In Community Care Workers In South Africa As PEPFAR Moves Toward Local Implementation Of Programming

“Nearly a decade after it came into being, the President’s Emergency Plan for AIDS Relief (PEPFAR) … is moving increasingly to support local leadership and implementation capacity” in South Africa, GlobalPost’s “Global Pulse” blog reports. “And given the South African health system’s weaknesses in the face of the magnitude of AIDS and TB, that means an investment in … lay listeners with just a few weeks of training,” who can discuss treatment and other issues with patients, the blog writes. The blog profiles Goodness Henama, “one of 22 community care workers in Wallacedene township, in the Cape Town suburb of Kraainfontein.”

U.S., Nigeria Inaugurate Defense Reference Laboratory In Abuja

U.S. Ambassador to Nigeria Terence McCulley spoke on Monday in Abuja at the inauguration of a Defense Reference Laboratory, Leadership reports, noting he said the laboratory, “which is the first of its kind in the sub-region,” was supported by U.S. funding. According to the newspaper, McCulley said the Reference Laboratory Program is part of U.S. assistance to Nigeria through a partnership between the U.S. Department of Defense (DOD) and Nigeria’s Ministry of Defense (NMOD) through the Walter Reed Program (WRP-N) and the Emergency Plan Implementation Committee (EPIC), which began in 2005 (8/30).

Global Fund Board Approves 45 New Two-Year Grants As Part Of Transitional Funding Mechanism

“The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria has approved 45 new two-year grants, from 37 countries, totaling $419.2 million, to fund essential prevention, treatment, and care services provided to the people affected by the three diseases,” according to a Global Fund press release. “Another 11 proposals worth a total of $91.2 million were sent back for revision, and are subject to a further independent technical review before they can be approved,” the press release adds, noting the grant approvals are part of the Transitional Funding Mechanism and “will bridge the financing of essential interventions until the next opportunity to apply for grants” (8/28). According to the U.N. News Centre, the Global Fund “has approved funding of $22.9 billion for more than 1,000 programs in 151 countries, and helped programs provide AIDS treatment for 3.6 million people, anti-tuberculosis treatment for 9.3 million people, and 270 million insecticide-treated nets for the prevention of malaria” (8/28).

GeneXpert TB Test Maker Cepheid Signs Deals With PEPFAR, USAID, Others To Provide Lower-Cost Kits

Diagnostics company Cepheid on Monday signed deals with PEPFAR, USAID, UNITAID, and the Bill & Melinda Gates Foundation to immediately reduce the price of its Xpert MTB/RIF test kit for its GeneXpert tuberculosis (TB) diagnostic system in 145 countries, Reuters reports. “The agreements will see the test sold for $9.98, down from its current price of $16.86 per test,” the news service writes, adding, “Cepheid said the Bill & Melinda Gates Foundation will make an initial payment of $3.5 million to make the test immediately available at the lower price” (Ail, 8/6).

Drug Companies Developing Novel Treatments For MDR-TB

With incentives to find new antibiotics signed into U.S. law last month, “multiple players are vying for the lead in the [multi-drug resistant tuberculosis (MDR-TB)] drug development niche,” Nature Medicine reports. “The fifth reauthorization of the U.S. Prescription Drug User Fee Act (PDUFA), signed into law on 9 July, includes a subsection called the Generating Antibiotic Incentives Now (GAIN) Act that aims to spur development of antibiotics for drug-resistant bacteria, including MDR-TB,” the news service writes, noting, “Drug makers that ask for approval of medicines to treat these pathogens will receive priority review, as well as five additional years of market exclusivity and fast-track status.” Currently, MDR-TB treatment “involves a bevy of regular tuberculosis medicines that, in many cases, must be administered for as long as two years or more … [and] don’t always work,” Nature Medicine states, adding, “The hope is that new medicines will shorten treatment times and improve cure rates.” The article discusses several medicines that are in different phases of research (Willyard, 8/6).

U.S. Support Of PEPFAR, Global Fund Helping To Achieve Global AIDS, TB, Malaria Goals

In this post in Huffington Post’s “Impact” blog, Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, examines “the success of U.S. efforts to promote better global health through support for [PEPFAR] and the Global Fund to Fight AIDS, Tuberculosis and Malaria.” She highlights U.S. Secretary of State Hillary Clinton’s recent trip to Africa, writing that Clinton’s “encouraging words” at the Reach Out Mbuya health center in Uganda reinforced U.S. commitment to an AIDS-free generation. She notes both PEPFAR and the Global Fund have supported the center and adds that “through hundreds of similar local programs all over the world, the Global Fund provides treatment to 3.6 million people who are HIV-positive.”

Health Workers Feeling Effects Of Staff, Supply Shortages At Clinics In Southwestern Uganda

Health workers with Medical Teams International, a medical non-governmental organization, “say they are overwhelmed” by high demand at five health clinics in two southwestern Ugandan refugee centers, PlusNews reports. The refugees, “many of whom came from conflict-prone areas of the Democratic Republic of Congo (DRC),” and local residents are in need of HIV and tuberculosis (TB) prevention information, and care and treatment services, according to the news service. “Uganda suffers from a chronic shortage of health workers — less than half of the vacant health positions are filled — but the recent influx of refugees fleeing violence in neighboring DRC has put even more pressure on [the region's] health services,” PlusNews writes. Physicians, who see 30 to 50 patients daily and often work double shifts, say gaps in the supplies of antiretroviral (ARV) and TB drugs poses concern, as does trying to follow-up with patients who may not return for visits, the news service notes (3/29).

South Africa Announces Initiative To Test Thousands Of Miners For TB

“South Africa wants to test hundreds of thousands of miners for tuberculosis [TB] and ensure sufferers get treatment over the next year,” David Mametja, head of South African National Department of Health’s TB program, said Tuesday at a workshop organized by the Stop TB Partnership, the Associated Press/Washington Post reports. Mametja “said the government is concerned the high prevalence of the disease among miners is holding an entire region back in the fight against TB,” and that while “it may be impossible to reach the nearly 600,000 miners in South Africa in one year, even those at highest risk in the gold industry, … setting an ambitious target is a way to show ‘it’s not business as usual,’” the AP writes.

Lancet Editorial Calls For TB Control, Elimination Efforts To Be On G20 Agenda

In anticipation of World Tuberculosis (TB) Day, commemorated on March 24, this Lancet editorial examines TB control and elimination efforts in 2012 and beyond. “Tuberculosis killed 1.45 million people in 2010 and about 500,000 people have drug-resistant disease,” the editorial states, adding, “Despite a woeful funding gap in 2012 of $1.7 billion, tuberculosis incidence is falling (from 9.4 million in 2009 to 8.8 million in 2010).” The editorial notes, “Ten new or repurposed tuberculosis drugs are in Phase II or III trials, which hopefully will reduce treatment times to about four months, compared with present multidrug-resistant tuberculosis regimens lasting 18-24 months,” adding, “Faster treatment will greatly improve adherence, reduce transmission, and cut costs.”